SCHEMBL6169511

SCHEMBL6169511

COc1ccc(C(=O)Nc2ccccc2C(=O)Nc2ccc3cn[nH]c3c2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 10/20 0.68
RAB9A P51151 9/20 0.68
SMN1; SMN2 Q16637 2/20 0.66
KDM4E B2RXH2 2/20 0.66
LMNA P02545 1/20 0.66
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
POLB P06746 1/20 0.62
PKM P14618 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
HPGD P15428 1/20 0.60
MAP4K4 O95819 1/20 0.59
CLK2 P49760 1/20 0.59
DYRK1A Q13627 1/20 0.59
SRPK1 Q96SB4 1/20 0.59
CLK4 Q9HAZ1 1/20 0.59
RXFP1 Q9HBX9 2/20 0.58
ALDH1A1 P00352 1/20 0.58
F2 P00734 1/20 0.58
MAPT P10636 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7369804 0.90 NPC1 (0.82) NPC1RAB9ASMN1; SMN2KDM4ELMNA
SCHEMBL6170427 0.89 NPC1 (0.70) NPC1RAB9ASMN1; SMN2KDM4ELMNA
SCHEMBL6170774 0.87 NR1H4 (0.62) NPC1RAB9ASMN1; SMN2HPGDMAP4K4
SCHEMBL6169797 0.83 NPC1 (0.61) NPC1RAB9AMEN1KMT2APOLB
SCHEMBL6171154 0.83 NPC1 (0.71) NPC1RAB9ASMN1; SMN2KDM4ELMNA
SCHEMBL15764664 0.81 NPC1 (1.00) NPC1RAB9AMEN1KMT2AMAP4K4
SCHEMBL29429758 0.80 RAB9A (0.80) NPC1RAB9ASMN1; SMN2KDM4EHPGD
SCHEMBL3378320 0.80 RAB9A (0.80) NPC1RAB9ASMN1; SMN2KDM4EHPGD
Hydrochloric Acid SCHEMBL7368705 0.79 RAB9A (0.78) NPC1RAB9ASMN1; SMN2KDM4EHPGD
SCHEMBL5226517 0.78 NPC1 (0.76) NPC1RAB9ASMN1; SMN2KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6372759-B1 BLOOD COAGULATION FACTOR XA FOR MAMMALS ELI LILLY AND COMPANY 2002-04-16 US claimed
EP-1019045-B1 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2005-06-08 EP disclosed
US-20030078431-A1 Antithrombotic agents BEIGHT DOUGLAS WADE (US) 2003-04-24 US disclosed
US-6500851-B2 ANTICOAGULANT IN MAMMLS ELI LILLY AND COMPANY 2002-12-31 US disclosed
US-20020173518-A1 Antithrombotic agents BEIGHT DOUGLAS WADE (US) 2002-11-21 US disclosed
EP-1019045-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2002-07-03 EP disclosed
US-6372759-B1 BLOOD COAGULATION FACTOR XA FOR MAMMALS ELI LILLY AND COMPANY 2002-04-16 US disclosed
EP-1019045-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-19 EP disclosed
WO-1999000128-A9 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 1999-08-05 WO disclosed
WO-1999000128-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173518-A1 Antithrombotic agents SERPINC1, TFPI, F11 NPC1 1604/4885RAB9A 3012/4885SMN1; SMN2 3287/4885
US-20030078431-A1 Antithrombotic agents SERPINC1, TFPI, F11 NPC1 1604/4885RAB9A 3012/4885SMN1; SMN2 3287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.